IS5453A - Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata - Google Patents

Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata

Info

Publication number
IS5453A
IS5453A IS5453A IS5453A IS5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A IS 5453 A IS5453 A IS 5453A
Authority
IS
Iceland
Prior art keywords
inhibitor
composition
aldose reductase
glycogen phosphorylase
reductase inhibitor
Prior art date
Application number
IS5453A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Jay Hoover Dennis
Hulin Bernard
Lee Treadway Judith
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5453A publication Critical patent/IS5453A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Noise Elimination (AREA)
IS5453A 1997-11-21 2000-04-14 Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata IS5453A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
IS5453A true IS5453A (is) 2000-04-14

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5453A IS5453A (is) 1997-11-21 2000-04-14 Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata

Country Status (38)

Country Link
EP (1) EP1032424B9 (is)
JP (1) JP2002504478A (is)
KR (2) KR20010032304A (is)
CN (1) CN1279617A (is)
AP (1) AP911A (is)
AR (1) AR016423A1 (is)
AT (1) ATE205403T1 (is)
AU (1) AU733304B2 (is)
BG (1) BG104435A (is)
BR (1) BR9814698A (is)
CA (1) CA2310069A1 (is)
DE (1) DE69801680T2 (is)
DK (1) DK1032424T3 (is)
DZ (1) DZ2656A1 (is)
EA (1) EA002365B1 (is)
ES (1) ES2161548T3 (is)
GR (1) GR3037071T3 (is)
GT (1) GT199800166A (is)
HR (1) HRP20000327A2 (is)
HU (1) HUP0100272A3 (is)
ID (1) ID24524A (is)
IL (1) IL135713A0 (is)
IS (1) IS5453A (is)
MA (1) MA26568A1 (is)
NO (1) NO20002164L (is)
OA (1) OA11379A (is)
PA (1) PA8462301A1 (is)
PE (1) PE135399A1 (is)
PL (1) PL340643A1 (is)
PT (1) PT1032424E (is)
SK (1) SK7222000A3 (is)
TN (1) TNSN98211A1 (is)
TR (1) TR200001451T2 (is)
UA (1) UA57811C2 (is)
UY (1) UY25258A1 (is)
WO (1) WO1999026659A1 (is)
YU (1) YU30700A (is)
ZA (1) ZA9810636B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536410A (ja) * 1999-02-12 2002-10-29 ノボ ノルディスク アクティーゼルスカブ 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
SG134333A1 (en) 2003-11-12 2007-08-29 Phenomix Corp Heterocyclic boronic acid compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
ES2388315T3 (es) 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
SG184168A1 (en) 2010-04-08 2012-10-30 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8940716B2 (en) 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
JP7072557B2 (ja) 2016-07-22 2022-05-20 ブリストル－マイヤーズ スクイブ カンパニー グルコキナーゼ活性化剤およびその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren

Also Published As

Publication number Publication date
WO1999026659A1 (en) 1999-06-03
ATE205403T1 (de) 2001-09-15
YU30700A (sh) 2002-12-10
PT1032424E (pt) 2001-12-28
ID24524A (id) 2000-07-20
MA26568A1 (fr) 2004-12-20
BG104435A (bg) 2001-01-31
EP1032424B9 (en) 2004-10-06
HUP0100272A2 (hu) 2001-06-28
EP1032424A1 (en) 2000-09-06
PL340643A1 (en) 2001-02-12
EP1032424B1 (en) 2001-09-12
OA11379A (en) 2004-01-28
NO20002164L (no) 2000-07-19
NO20002164D0 (no) 2000-04-27
AU9555898A (en) 1999-06-15
TNSN98211A1 (fr) 2005-03-15
GR3037071T3 (en) 2002-01-31
PE135399A1 (es) 2000-01-15
IL135713A0 (en) 2001-05-20
KR20010032304A (ko) 2001-04-16
CA2310069A1 (en) 1999-06-03
CN1279617A (zh) 2001-01-10
AU733304B2 (en) 2001-05-10
AP9801401A0 (en) 1998-12-31
HUP0100272A3 (en) 2002-11-28
DE69801680T2 (de) 2002-02-07
KR20010032300A (ko) 2001-04-16
PA8462301A1 (es) 2000-05-24
DZ2656A1 (fr) 2003-03-22
DE69801680D1 (de) 2001-10-18
SK7222000A3 (en) 2001-09-11
AP911A (en) 2000-12-07
AR016423A1 (es) 2001-07-04
ES2161548T3 (es) 2001-12-01
DK1032424T3 (da) 2001-11-19
EA002365B1 (ru) 2002-04-25
KR100661214B1 (ko) 2006-12-26
TR200001451T2 (tr) 2002-06-21
JP2002504478A (ja) 2002-02-12
EA200000433A1 (ru) 2000-12-25
GT199800166A (es) 2000-04-19
HRP20000327A2 (en) 2001-02-28
UY25258A1 (es) 2000-12-29
UA57811C2 (uk) 2003-07-15
ZA9810636B (en) 2000-05-22
BR9814698A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
IS5453A (is) Samsetning af aldósa redúktasa lata og glýkógen fosfórýlasa lata
DK0969846T4 (da) Sammensætninger og fremgangsmåder til reduktion af okulær hypertension
DK1064298T3 (da) Inhibitorer af caspaser
DK0748782T3 (da) Cementeringssammensætninger og anvendelse af sådanne sammensætninger i cementering af olie- eller tilsvarende borehuller
DK1696124T3 (da) Kombination af kammer og stempel
DK0915880T3 (da) Azolotriaziner og pyrimidiner
FI974436A0 (fi) Substituoituja N-(indoli-2-karbonyyli)-glysiiniamideja ja -johdannaisia glykogeenifosforylaasi-inhibiittoreina
NO20006488D0 (no) Sammensetning og anvendelse
DE69911127D1 (de) Kosmetische Tensid Zusammensetzung sowie ihre Verwendung
NO994216L (no) Sementsammensetninger og bionedbrytbare dispergeringsmidler derfor
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
ATE251892T1 (de) Schäumende öl-zusammensetzung und ihre verwendung
DK1047450T3 (da) Kombinationer af ACE-inhibitorer og MMP-inhibitorer
DK1112003T3 (da) Ny sammensætning og anvendelse
DK1060147T3 (da) Afbindingsforsinkende systemer og anvendelse ved oliebrøndscementering
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
ATE274024T1 (de) Sauerstoffabsorbierende zusammensetzung und ihre anwendungsmethode
NO986174L (no) Triazinderivater og anvendelse derav
ID23456A (id) Turunan-turunan pirolidina dan piperidina
EP1379633A4 (en) ENZYMATIC CHANGE OF SEEDS VAN PLANTAGO PSYLLIUM
AU1522400A (en) Substituted pyrimidine compositions and methods of use
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
DK1272456T3 (da) Angioneseinhibitorer på basis af hydrazid og alkoxyamid
DK1512685T3 (da) Imidazonaphthyridiner og deres anvendelse til induktion af cytokinbiosyntese